Metraipolis › archive › dc_9a72e243bb7f

Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian… — Europe PMC PMID:42809558

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42809558
DOI
10.1371/journal.pone.0358540
License (as archived)
solo-consultazione
Archived
2026-10-07T19:18:34.504Z
SHA-256 of the archived text
aa114fedcfe7cbd536782d60763db312473ad898aa8223ae07d9bf72145deff9
Stable URL of this page
https://metraipolis.com/documento/dc_9a72e243bb7f

How to cite

Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian… — Europe PMC PMID:42809558 — Europe PMC (en), https://europepmc.org/article/MED/42809558 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9a72e243bb7f (Metraipolis archive dc_9a72e243bb7f, sha256 aa114fedcfe7cbd536782d60763db312473ad898aa8223ae07d9bf72145deff9)
BibTeX
@misc{dc9a72e243bb7f,
  title = {Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian… — Europe PMC PMID:42809558},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42809558},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9a72e243bb7f; sha256 aa114fedcfe7cbd536782d60763db312473ad898aa8223ae07d9bf72145deff9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42809558. Agents can read the archived copy with the MCP tool read_document.